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A 2016 synopsis 
Daniel L. Peterson 
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E-mail: dpeterson@sierrainternalmed.com. 
ME/CFS, a complex multisystem disease of diverse etiology, which results 
in significant functional and costly impairment, is estimated to affect approx-
imately 40,000 Swedish residents.  This synopsis describes developments 
by governmental agencies (i.e. the CDC); emerging clinical centers in Stock-
holm and Gothenburg, and the sophisticated Swedish research addressing 
basic and translational medicine, and physician education.  A model is pre-
sented for Centers of Excellence, additional issues addressed: name chan-
ge controversy, subsetting of patients, Big Data and Precision medicine, the 
microbiome, and current treatment challenges. Research obstacles and so-
lutions are outlined including the profound lack of funding and attention af-
forded by government agencies, academic institutions, and pharmaceutical 
industry.  Development of C.O.E.’s and optimism; based on new science and 
technology with worldwide collaboration, suggest hope for the future.
Myalgic Encephalomyelitis (ME/
CFS) is a complex multi-system di-
sease of probable diverse etiology and 
pathogenesis resulting in significant 
functional impairment.  Significantly, 
the fatigue is generally worsened by 
physical or mental exertion. Com-
mon symptoms include cognitive dys-
function, autonomic manifestations 
of dysfunction, sleep abnormalities, 
pain, and GI complaints.  Worldwide 
studies have indicated that when app-
ropriately screened and diagnosed, 
the incidence rates are similar in the 
developed countries where it has been 
studied.  A conservative estimate sug-
gests that over 1 million Americans 
suffer from ME/CFS and further, 
that a significant proportion (>25%) 
are severely affected or disabled. 
Current State of Affairs in the  
U.S. and Sweden
Centers for Disease Control and Pre-
vention (CDC) in Atlanta, Georgia, is 
embarking on a collaborative innova-
tive process in order to properly revise 
its educational materials.  They have 
developed a Technical Development 
Work group (TDW) to identify the 
needs and priority topics for educatio-
nal materials.  The emphasis will be 
on evidence-based, understandable 
materials that are useful to all stake-
holders.  Hopefully, these reports and 
efforts will be available in translated 
form to interested parties including 
physicians, patients, and research or-
ganizations worldwide.  The recent 
efforts by the National Institutes of 
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Health (NIH) in the United States to 
prioritize the study of ME/CFS are 
encouraging. Without a significant 
increase in funding for these efforts, 
however, it is unlikely that either the 
intramural or extramural programs 
will make rapid or substantial pro-
gress in this difficult field. 
There is a certain recognition of 
ME/CFS in Sweden, it’s effect on the 
citizenry and cost to society. This has 
resulted in excellent research targeted 
at immunological and pathological 
determinants of ME/CFS. However, 
access to care at the primary care level 
remains problematic.  The relatively 
newly established clinic in Stockholm 
is an excellent start to remedy this 
problem.  It would appear prudent 
för researchers and clinicians world-
wide to collaborate in a networking 
fashion.  This would ultimately allow 
for targeted research in countries and 
institutions with special expertise in 
the various aspects of the disease, as 
well as reaching consensus on appro-
priate diagnostic criteria, subsetting 
of patient groups, determination of 
endpoints for study, and appropriate 
therapeutic strategies.  As in all other 
chronic diseases, the driving force for 
these efforts must come from the pa-
tient groups and advocates in order 
to raise awareness in the appropriate 
government and private agencies to 
obtain the priority status and funding 
necessary to solve ME/CFS.
Sweden is unique in having a very 
well organized and functional na-
tional patient support organization, 
with local groups in the larger cities 
of Stockholm, Goteborg and Malmo. 
This patient organization is active in 
lobbying the government for necessa-
ry infrastructure, reform and funding.
Jonas Bergquist, PhD, at Uppsala 
University has been very instrumen-
tal in spearheading basic research into 
the biochemical metabolomics and 
proteomics in the serum and spinal 
fluid of patients severely affected by 
ME/CFS.  The Gottfries Clinic in 
Molndal, Sweden, continues with its 
efforts to meet the demands of pa-
tients for diagnosis and treatment of 
fibromyalgia as well as ME/CFS. Jo-
nas Blomberg, MD, PhD, a retired 
professor of clinical virology, remains 
active in his study of the role of viru-
ses and immunity in the development 
Figure 1. ME/CFS Prevalence and Severity World-wide.
Prevalence in the USA:
Estimated 400/100,000 ≈ over 1 million patients 
Prevalence in Sweden:
About 40.000 patients are estimated to have ME in Sweden 
Prevalence World Wide:
≈19 million 
Prevalence of Severe Cases of ME/CFS:
Approximately 25% of all patients are classified as “severe”
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of ME/CFS.  Dr. Per Julin continues 
to develop and expand the ME/CFS 
clinic in Stora Skondal. Other physici-
ans and centers are striving to deve-
lop appropriate institutions or clinics 
to serve the approximately 40,000 pa-
tients with ME/CFS in Sweden.  
Most of the world’s medical schools 
and medical textbooks do not include 
ME/CFS in their curriculum or pu-
blications, other than perhaps brief 
summaries and suggestions for symp-
tomatic therapy. 
While education of primary care 
physicians and other practitioners is 
critical to the field, Centers of Ex-
cellence appear to be the most cost 
effective and viable approach to ex-
pediting translational medicine (the 
process of bringing bench research to 
the efficient diagnosis and treatment 
of patients). Worldwide collaboration, 
as exists in many other diseases such 
as multiple sclerosis, AIDS, and dia-
betes, would be ideal. It is difficult to 
establish the necessary infrastructu-
res, particularly in view of differing 
funding mechanisms and distribu-
tion systems for medical care in dif-
ferent countries and diverse cultures. 
A Nordic coalition, however, might 
be plausible and should be explored. 
The National Center for Neuroim-
munology and Emerging Diseases at 
Griffith University in Australia has 
been highly successful in developing 
the translational medicine concept, 
conducting state of the art basic and 
clinical research while simultaneously 
engaging in clinical diagnostic and 
treatment endeavors.  
Name Change Controversy
In spite of the extensive publicity 
and discussion of the Institute of 
Medicine’s (IOM) recommendations 
to establish new criteria for ME/CFS, 
there has not been broad support for 
adopting or endorsing SEID.  While 
the clinical definition is very user 
friendly (it can be applied quickly by 
inexperienced clinicians), it is the ge-
neral feeling that it does not capture 
a homogenous population. Leonard 
Jason, psychologist and researcher, 
has indicated that the SEID defini-
tion captured most of classically de-
fined ME/CFS patients but included 
• Direct $9 billion USD 
annually
– [approx. $70 billion 
Swedish Kronor]
• Indirect $17-$24 bil-
lion USD annually
– [ approx. $140-$200 bil-
lion Swedish Kronor] 
Figure 2. Economic Impact of ME/CFS. Annual Economic Loss Due to ME/CFS
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a larger and less specifically uniform 
patient cohort.
Without acceptance by agencies 
such as the CDC, NIH, or WHO the 
definition may not be widely adop-
ted.  Additionally, in light of ongoing 
research initiatives, basic as well as 
clinical researchers have continued to 
use the long established and accepted 
definitions including the Canadian 
Consensus Criteria (CCC) and/or the 
1994 CDC Criteria.  Certainly there 
will continue to be re-evaluation and 
discussions of the appropriate use of 
these established and newly proposed 
definitions due to the heterogeneous 
nature of the patient populations. 
Consensus, of course, is the ultimate 
goal.
Research Developments 
Subsetting ME/CFS Patients
The heterogeneous nature of the po-
pulations obtained by the various de-
finitions suggest that researchers and 
Figure 3. SEID Diagnostic Algorithm for ME/CFS
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clinicians must continue efforts at 
categorizing patients into subsets in 
order to determine the etiology and 
pathogenesis and, ultimately, the most 
appropriate treatment.  Examples in-
clude the ongoing clinical trials in 
Norway and the UK with rituximab 
in patients presumed to have an au-
toimmune component to their patho-
genesis. An example of translational 
medicine can be found in the work 
of professor Carmen Scheibenbogen 
of Berlin, Germany, describing auto-
antibodies to adrenergic and acetyl-
choline receptors in ME/CFS patients 
which has both diagnostic and thera-
peutic implications for the patients. 
This may aid in understanding the au-
toimmune pathophysiology in a sub-
set of patients. Such stimulating and 
exciting initial results, mandate addi-
tional and replicating studies. 
After more than 30 years of stud-
ying ME/CFS worldwide, the prepon-
derance of evidence continues to sug-
gest a role of immune perturbation/
dysfunction in the production of the 
signs and symptoms of the disease. 
As molecular biology has become 
fine tuned, researchers are capable 
of studying the nuances of B, T and 
Natural Killer Cell function. Many 
of the reported abnormalities such as 
impaired Natural Killer Cell function 
have been reproduced in independent 
laboratories. However, there is yet to 
be universal agreement as to the sensi-
tivity and specificity of biomarkers for 
diagnosis or treatment.
Big Data and Precision Medicine
ME/CFS is a Big Data gold mine. 
Big Data has become in vogue as an 
approach utilizing statistical metho-
dology and modeling to study ME/
CFS and many other clinical illnesses. 
While this approach is clearly of great 
potential, particularly with respect 
to precision medicine, it requires lar-
ge numbers of patients and is a very 
costly approach to diagnosis.  On the 
other hand, there remains a concern 
as to whether findings obtained in a 
small group of patients, such as the 
proposed NIH intramural study of 
40 patients and controls, or the Stan-
ford Initiative with 20 severely affec-
ted patients, will be applicable to the 
greater ME/CFS patient population. 
Worldwide, patients, clinicians, and 
researchers are anxiously awaiting the 
results of these preliminary studies 
utilizing the Big Data technology ap-
proach to the study of ME/CFS.
Precision medicine is yet another 
trend in medical research.  Some suc-
cess has been obtained, for example, 
in identifying the correct chemothera-
peutic agent for treatment of various 
cancers, eliminating the inaccuracy 
and potential complications of trial 
and error therapy even when utilizing 
evidence-based studies. The NIH re-
cently awarded $55M for fiscal year 
2016 to launch the Precision Medicine 
Initiative (PMI). This is a landmark 
research effort that aims to engage 
one million participants to prevent 
and treat disease based on lifestyle, 
environment and genetics. Perhaps 
ME/CFS patients will ultimately be-
nefit from this effort.  It remains to be 
determined whether these approaches 
utilizing genetic profiles, gene ex-
pression studies, metabolomics, etc., 
will have general applicability to the 
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diagnosis and treatment of patients 
with ME/CFS. Precision medicine is 
certainly a lofty goal with the poten-
tial for increased sensitivity and spe-
cificity of diagnosis and cost effective 
therapies.  
The Gut Microbiome and ME/CFS
There is increasing evidence that 
the human microbiome is influenced 
by many factors and the status of the 
gut microbiome has significant impact 
on immunological function.  This is 
an extremely complex area of study. 
The pursuit has been taken up by nu-
merous well-respected research insti-
tutions including Columbia and Cor-
nell Universities in New York. The 
potential utility for understanding 
the pathogenesis of ME/CFS or for 
determining strategies for treatment, 
remains to be determined. Hopefully, 
adequate funding for further large 
studies will be forthcoming.
Treatment of ME/CFS
Treatment of ME/CFS remains chal-
lenging and problematic.  Since the 
publication of the P2P and IOM do-
cuments, there is agreement that ad-
ditional work must be done in deter-
mining outcome measures for clinical 
trials. In addition, determination of 
appropriate interventions for clinical 
trials and execution at multiple sites 
with well-characterized subsets of 
patient populations are needed.  Un-
fortunately, there has been little inte-
rest from the pharmaceutical industry 
which, in general, is the driving force 
behind well-constructed and funded 
clinical trials.  It is hoped that agencies 
such as the FDA and others might be 
engaged in the effort to design app-
ropriate clinical trials and even sup-
port their execution.  In the interim, 
clinicians on the front line of patient 
care must utilize the art of medicine 
in selecting modalities of interven-
tion that have been demonstrated to 
potentially affect quality of life or 
prevent the devastating complications 
and comorbidities of chronic disab-
ling illness. Large well-funded studies 
are required for international collabo-
ration, particularly when studying ge-
netics and gene expression of complex 
yet relatively frequent diseases such as 
ME/CFS. These should be conducted 
in well designed and executed studies 
at multiple sites utilizing only well 
characterized patients.
Obstacles and Solutions
As the P2P and IOM documents 
clearly point out, ME/CFS research 
has been fragmented and fraught with 
methodological pitfalls such as use 
of different disease definitions, lack 
of objective endpoints, small patient 
numbers, lack of control groups, fai-
lure to replicate results and numerous 
other short comings. The studies have 
largely lacked the scientific rigor suf-
ficient for the world of evidence ba-
sed diagnosis and management. Some 
of these stumbling blocks have been 
overcome by general acceptance of 
case definitions, emphasis on subsets 
and rigorous study designs. Yet, many 
obstacles remain for the nascent re-
searchers and clinicians in this diffi-
cult and complex illness.  
The largest of these obstacles is the 
failure of the scientific world (and in 
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some cases the patient community) to 
accept the existence of ME/CFS as a 
real, organically based disease, and as-
sociated with extreme disability. Fled-
gling efforts have been further ham-
pered by profound lack of funding of 
the magnitude necessary to conduct 
even the basic rigorous studies and 
treatment interventions.  Govern-
ment agencies, academic institutions 
and the pharmaceutical industry have 
ignored the call to action, leaving fun-
ding to small grants and private do-
nations.  
It may be useful to remind oursel-
ves of the magnitude of ME/CFS in 
the world in human and economic 
terms.  Clearly such large numbers 
should justify the resources necessary 
to intensely study the disease and al-
leviate the concomitant disability and 
economic cost to all societies.  
Using basic patient’s samples 
such as blood, urine, saliva and CSF 
sophisticated research can be done on 
DNA, RNA, epigenetic markers, pro-
teins, metabolites and immune cells 
and their messenger cytokines and 
chemokines.   
New technology such as high out-
put sequencing, big data mining, etc. 
will provide the necessary tools to sol-
ve these problems, but adequate fun-
ding must be obtained.  It has been 
guesstimated that with adequate fun-
ding such as that allocated to other 
comparable old and emerging disease 
(e.g. Zika virus related disorders) ME/
CFS could be fully understood and 
treated in 3-5 years. While it is unlike-
ly that a single country or agency will 
step up to the financial plate, world-
wide collaboration could accomplish 
these goals.
In just the last few months the NIH 
has funded projects aimed at training 
patients to recognize exhaustion (pre-
cision medicine) and a broadly based 
large study to determine biomarkers 
(big data analysis and high tech mole-
cular biological techniques). 
Longitudinal studies to determine 
the natural history of ME/CFS are 
being conducted by the CDC at multi-
ple sites using common data elements, 
standardized testing and data analysis. 
The International Association for Ch-
ronic Fatigue Syndrome/Myalgic En-
cephalomyelitis (IACFS/ME) is again 
hosting their biannual meeting at the 
Weston Fort Lauderdale, October 27-
30. Participation by researchers and 
clinicians, and patients are of course 
welcomed and encouraged.
One of the most unique and ubiqui-
tous symptoms of ME/CFS is post-
exertional fatigue following physical 
or cognitive challenge.  Many centers 
are now studying this symptom to de-
termine its cause, to seek a potential 
unique (sensitive and specific) biomar-
ker and determine potential therapeu-
tic interventions for this very disab-
ling symptom.
A few large, classically designed tre-
atment studies are being conducted 
while compassionate, empiric treat-
ment protocols remain the standard 
of care.
Recently major strides have been 
taken to achieve common goals in 
Europe. Phenomenal progress has 
been made over the past ten years in 
the UK through the effort of the In-
vest in ME UK Charity to stimulate 
research and patient and physician 
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education. As an example, the Invest 
in ME Research Charity has launched 
the foundation for a translational 
biomedical research Centre of Excel-
lence. It also sponsored a state of the 
art scientific meeting, affording invi-
ted scientists and clinicians the opp-
ortunity to share research and stra-
tegies while providing education and 
hope to patients and treating clinici-
ans.  The recent IIMEC11 conference 
presented stimulating new studies on 
case definitions, sub setting patient 
groups, the human, viral and bacterial 
gut microbiome, potential genetic and 
metabolomic biomarkers, and second 
generation research on a wide variety 
of immune markers including NK 
cells, B cells and cytokines.  With pro-
per support and leverage these areas 
all present viable and promising po-
tential for future clinical researchers 
and clinicians.
Representatives of 13 countries in 
Europe have joined the European ME 
Research Group (EMERG) for inter-
national collaboration. This repre-
sents a major step in the development 
of a necessary regional infrastructure 
to support new research initiatives. 
Such collaborative efforts will maxi-
mize research speed and efficiency.
Conclusion
Throughout the world, access to care 
remains problematic for patients with 
ME/CFS.  There remains a lack of 
knowledge on the part of most phy-
sicians at both the primary care and 
specialty level with respect to ME/
CFS in general and particularly in 
the area of diagnosis and appropriate 
treatment.  Strategies implemented to 
date have had limited success in en-
couraging clinicians to specialize in 
the area of ME/CFS or to even make 
an appropriate diagnosis.  Given the 
long duration of this gaping hole in 
the provision of medical care, many 
experts feel that the appropriate fun-
ding and establishment of Centers of 
Excellence may be the most viable 
approach for educating physicians 
and ancillary personnel.  Alas, while 
there is widespread support amongst 
patient groups and clinicians, the fun-
ding and infrastructure is not endor-
sed or supported for this approach. 
And yet, never before have the tools 
been so efficient and available for the 
study of complex diseases and the fu-
ture is optimistic if the obstacles afo-
rementioned and the many others can 
be uniformly overcome.
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